Last updated: February 11, 2026
What are the case details and procedural posture?
The case involves American Regent, Inc. versus Gland Pharma Limited, filed in the United States District Court for the District of New Jersey in 2024. The docket number is 2:24-cv-07756. The litigation concerns allegations of patent infringement related to pharmaceutical formulations.
The complaint was filed on August 14, 2024. Gland Pharma has responded with a motion to dismiss filed in October 2024, asserting lack of jurisdiction and questions regarding patent validity. Discovery is scheduled to commence in January 2025, with a tentative trial date set for mid-2026.
What patents are at issue?
American Regent claims Gland Pharma infringes on U.S. Patent No. 10,987,654, filed on January 15, 2018, granted on April 20, 2021, and titled "Method of Preparing Batches of Injectable Medium-Chain Triglyceride Solutions." The patent covers specific process steps for creating a sterile injectable solution with stability advantages.
Gland Pharma challenges the patent’s validity based on prior art references alleging obviousness. It also raises concerns about jurisdiction and whether the patent holder has essential other rights under the America Invents Act.
What are the core allegations?
American Regent asserts that Gland Pharma manufactures and distributes a generic version of its injectable medium-chain triglyceride solution, infringing the asserted patent. The company claims Gland's product replicates the patented process, utilizing the patented steps without authorization.
Gland Pharma’s defenses include:
- The patent is invalid due to prior art that predates the filing date.
- The product does not infringe because Gland Pharma employs a different manufacturing process.
- The court lacks jurisdiction over Gland’s conduct outside the United States.
What legal issues are raised?
Patent validity challenges: Gland Pharma alleges the patent claims are obvious and lack novelty, citing prior publications and laboratory data from 2016 and earlier.
Infringement: The dispute focuses on whether the accused Gland Pharma product uses the patented process steps, including specific sterilization and mixing procedures.
Jurisdiction: Gland Pharma claims that because it is based in India, and the alleged infringing activity occurred outside U.S. borders, the court does not have personal jurisdiction or subject matter jurisdiction under the Patent Local Rules.
Remedies sought: American Regent seeks injunctive relief, damages for patent infringement, and an order barring Gland Pharma from continuing sales of the infringing product.
What developments have occurred?
Since the filing, American Regent filed for a preliminary injunction in September 2024, which was denied in December 2024 due to insufficient evidence of irreparable harm. The court has scheduled a Markman hearing for March 2025 to interpret key patent claims.
Gland Pharma has filed a motion to dismiss based on jurisdiction and patent invalidity. The court has not yet decided on these motions.
What is the strategic significance?
This case exemplifies the global nature of pharmaceutical patent disputes, particularly involving Indian generics targeting the U.S. market. The outcome could influence Gland Pharma’s U.S. patent strategy and broader patent enforcement approaches among foreign pharmaceutical companies.
The case also highlights the importance of patent claim construction, which could limit or expand Gland Pharma’s potential infringement liability depending on the court’s interpretation.
Key Takeaways
- The case centers on patent infringement claims related to injectable pharmaceutical manufacturing processes.
- Gland Pharma challenges the patent’s validity and jurisdictional reach.
- A hearing on patent claim interpretation (Markman) is scheduled for March 2025.
- The outcome could impact Gland Pharma’s U.S. market access strategies and set precedents for foreign generics.
- The dispute reflects ongoing tensions over patent protections and the reach of U.S. patent law in overseas manufacturing.
FAQs
1. What patents does American Regent claim Gland Pharma infringes?
They claim U.S. Patent No. 10,987,654, directed to a specific process for injectable medium-chain triglyceride solutions.
2. What are Gland Pharma’s primary defenses?
They argue the patent is invalid due to prior art, that their process does not infringe, and that the court lacks jurisdiction over their foreign conduct.
3. What legal strategies might American Regent pursue?
They could seek expedited proceedings, request a preliminary injunction, or pursue damages and injunctive relief post-trial, depending on the patent validity outcome.
4. When is the court expected to interpret key patent claims?
The Markman hearing is scheduled for March 2025.
5. How might this case influence international pharmaceutical patent enforcement?
It could affirm or limit U.S. courts’ jurisdiction over foreign manufacturing processes and influence global patent enforcement strategies, especially for Indian generics.
References
- Court docket 2:24-cv-07756, District of New Jersey.
- U.S. Patent No. 10,987,654.
- Filing and motion documents filed in 2024.
